Human CYP2C19 ELISA Kit (V2LY-0626-LY5564)

See all CYP2C19 antibodies
Go to compare Compare Online Inquiry
Tested Data
Datasheet
SDS
Request for COA
Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Sensitivity
0.053 ng/mL
Detection Range
0.1-40 ng/mL
Sample Type
Serum, Plasma, cell culture supernates
Specificity
Human
Assay Type
Sandwich
Reactivity
Human
Assay Time
1.5 h
Molecule Mass
55.9 kDa
Components
  • Pre-coated ELISA Plate: 12 wells * 8 detachable strips
  • Standard solution: 0.5ml x1
  • Standard diluent: 3ml x1
  • Streptavidin-HRP: 6ml x1
  • Stop solution: 6ml x1
  • Substrate solution A: 6ml x1
  • Substrate solution B: 6ml x1
  • Wash buffer concentrate (25x): 20ml x1
  • Biotinylated antibody: 1ml x1

Formulations & Storage [For reference only, actual COA shall prevail!]

Storage
Store at 2-8°C
More Infomation

Target

Full Name
Cytochrome P450 Family 2 Subfamily C Member 19
Function
A cytochrome P450 monooxygenase involved in the metabolism of polyunsaturated fatty acids (PUFA) (PubMed:18577768, PubMed:19965576, PubMed:20972997).

Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:18577768, PubMed:19965576, PubMed:20972997).

Catalyzes the hydroxylation of carbon-hydrogen bonds. Hydroxylates PUFA specifically at the omega-1 position (PubMed:18577768).

Catalyzes the epoxidation of double bonds of PUFA (PubMed:20972997, PubMed:19965576).

Also metabolizes plant monoterpenes such as limonene. Oxygenates (R)- and (S)-limonene to produce carveol and perillyl alcohol (PubMed:11950794).

Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine. Hydroxylates fenbendazole at the 4' position (PubMed:23959307).
Biological Process
Drug metabolic process Source: BHF-UCL
Epoxygenase P450 pathway Source: GO_Central
Exogenous drug catabolic process Source: BHF-UCL
Heterocycle metabolic process Source: BHF-UCL
Monoterpenoid metabolic process Source: BHF-UCL
Omega-hydroxylase P450 pathway Source: Reactome
Organic acid metabolic process Source: GO_Central
Steroid metabolic process Source: BHF-UCL
Xenobiotic metabolic process Source: GO_Central
Cellular Location
Endoplasmic reticulum membrane; Microsome membrane

Botton, M. R., Whirl‐Carrillo, M., Del Tredici, A. L., Sangkuhl, K., Cavallari, L. H., Agúndez, J. A., ... & Gaedigk, A. (2021). PharmVar GeneFocus: CYP2C19. Clinical Pharmacology & Therapeutics, 109(2), 352-366.

Koopmans, A. B., Braakman, M. H., Vinkers, D. J., Hoek, H. W., & van Harten, P. N. (2021). Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19. Translational psychiatry, 11(1), 1-16.

Wang, Y., Meng, X., Wang, A., Xie, X., Pan, Y., Johnston, S. C., ... & Wang, B. (2021). Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA. New England Journal of Medicine, 385(27), 2520-2530.

Pratt, V. M., Del Tredici, A. L., Hachad, H., Ji, Y., Kalman, L. V., Scott, S. A., & Weck, K. E. (2018). Recommendations for clinical CYP2C19 genotyping allele selection: a report of the association for molecular pathology. The Journal of Molecular Diagnostics, 20(3), 269-276.

Cavallari, L. H., Lee, C. R., Beitelshees, A. L., Cooper-DeHoff, R. M., Duarte, J. D., Voora, D., ... & IGNITE Network. (2018). Multisite investigation of outcomes with implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention. JACC: Cardiovascular Interventions, 11(2), 181-191.

Dean, L. (2018). Clopidogrel therapy and CYP2C19 genotype. Medical Genetics Summaries [Internet].

El Rouby, N., Lima, J. J., & Johnson, J. A. (2018). Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert opinion on drug metabolism & toxicology, 14(4), 447-460.

Jukić, M. M., Haslemo, T., Molden, E., & Ingelman-Sundberg, M. (2018). Impact of CYP2C19 genotype on escitalopram exposure and therapeutic failure: a retrospective study based on 2,087 patients. American Journal of Psychiatry, 175(5), 463-470.

Empey, P. E., Stevenson, J. M., Tuteja, S., Weitzel, K. W., Angiolillo, D. J., Beitelshees, A. L., ... & IGNITE Network. (2018). Multisite investigation of strategies for the implementation of CYP2C19 genotype‐guided antiplatelet therapy. Clinical Pharmacology & Therapeutics, 104(4), 664-674.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Human CYP2C19 ELISA Kit?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols

Related Products

Mouse Anti-CYP2C19 Recombinant Antibody (CBWJC-3552) (CAT#: V2LY-0125-LY952)

Mouse Anti-CYP2C19 Recombinant Antibody (EG895) (CAT#: V2LY-0125-LY953)

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry
Request bulk or custom quote Second antibody and isotype control

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

online inquiry
Online Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.